VOR

Vor Biopharma Inc. (VOR) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Vor Biopharma Inc. is a clinical-stage biopharmaceutical company focused on developing telitacicept, a dual-target recombinant fusion protein for autoimmune diseases. In June 2025, the company in-licensed telitacicept from RemeGen Co., Ltd. for exclusive rights outside Greater China. The company is currently conducting global Phase 3 clinical trials for telitacicept in generalized myasthenia gravis (gMG) and Sjögren's disease (SjD). The company has no commercial revenue and relies on capital raises to fund operations.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. Q1 2025 cash figures adjusted for context; Q1 2026 includes significant investment in marketable securities.

Material Changes vs. Prior Period

• Net Loss Expansion: Net loss increased significantly to $219.6 million from $32.5 million in Q1 2025. This was primarily driven by a $188.4 million non-cash charge related to the change in fair value of warrant liabilities.
• Operating Expenses: Total operating expenses increased slightly to $35.2 million.
  • R&D Expenses: Decreased to $17.6 million (from $26.7 million) due to the wind-down of legacy programs (Trem-cel, VCAR33) and reduced personnel/manufacturing costs, partially offset by $12.3 million in new spend for telitacicept programs.
  • G&A Expenses: Increased to $17.6 million (from $6.6 million), driven by a $7.4 million increase in stock-based compensation and higher personnel costs for new executives.
• Liquidity Position: Cash and marketable securities grew to $491.5 million, supported by a $74.9 million private placement in March 2026 and proceeds from prior year offerings. The company invested heavily in marketable securities ($276.5 million purchases) during the quarter.
• Capital Structure: The company completed a 1-for-20 reverse stock split in September 2025. As of March 31, 2026, there were 54.2 million shares of common stock outstanding.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management expects existing cash, cash equivalents, and marketable securities ($491.5 million) to fund operations into early 2029.
• Clinical Milestones:
  • gMG: Global Phase 3 trial is recruiting; topline data anticipated in the first half of 2027.
  • SjD: Global Phase 3 trial initiated in March 2026; targeting ~250 patients.
• Key Risks:
  • Warrant Liability Volatility: The company has significant warrant liabilities ($638.5 million as of March 31, 2026) classified as liabilities. Changes in the company's stock price directly impact the fair value of these warrants, causing significant volatility in reported net loss.
  • Capital Requirements: The company expects to incur significant losses for the foreseeable future and will require substantial additional funding.
  • Third-Party Dependence: Reliance on RemeGen for data from China and third-party manufacturers for clinical supply.
  • Regulatory Uncertainty: No assurance that FDA will accept data from RemeGen's trials or that the company will obtain approval for telitacicept.

Investor Verification Checklist

• Verify the fair value methodology used for the $638.5 million warrant liability and its sensitivity to stock price fluctuations.
• Confirm the cash runway assumptions used to project funding into early 2029, given the high burn rate.
• Review the terms of the March 2026 private placement with TCGX affiliates, noting the related party transaction status.
• Assess the progress of patient enrollment in the global Phase 3 trials for gMG and SjD against management's targets.
• Monitor the status of the 2025 Warrants (PIPE and RemeGen), including exercise activity and potential dilution.